While #GLP1 is set to be the backbone of future #obesity therapy, similar to #PD1 in cancer, challenges in peptide manufacturing means there won't be the same flood of late-stage and commerical programs as was experienced in immuno-oncology $NVO $LLY $VKTX $RHHBY
About us
BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events. When you subscribe to BioCentury, our team of Ph.D.s, analysts and industry experts become an extension of your team, helping you answer critical questions, decipher strategic trends, objectively evaluate product and business strategies, and assess competitive, financial, and policy risks. We also help you to build your network by connecting you the who’s who in the industry. Watch the latest episodes of The BioCentury Show on YouTube www.biocenturyyoutube.com Subscribe to the "BioCentury This Week" podcast www.biocenturypodcast.com
- Website
-
http://www.biocentury.com
External link for BioCentury Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Redwood City, CA
- Type
- Privately Held
- Specialties
- Biotechnology, Pharmaceutical, Healthcare Ecosystem, Drug Development, Business Strategy, Policy, Regulatory, Finance, Deal Making, Venture Capital, and biopharma
Locations
-
Primary
Redwood City, CA 94065, US
Employees at BioCentury Inc.
Updates
-
What's Next For Translational Research? We're wrapping up the day with a closing rapporteur session identifying the key takeaway messages from BioCentury's inaugural #BioCenturyGrandRounds conference. Thank you to our panelists: Andrew Marshall, Scion Life Sciences Ania Payne, Biohub Nash Dan Roden, Vanderbilt University Medical Center Dan Zhang, Hillgene Moderators: Simone Fishburn, BioCentury Inc. David Flores, BioCentury Inc.
-
As pharma and investor interest in obesity, inflammation, immunity and neuroscience resurges, academic research is offering new targets, mechanisms and approaches to drive advancements in these fields. At #BioCenturyGrandRounds, the Disease Biology Boom session elucidated how emerging science may make drug developers better prepared to serve these large, chronic diseases than the last time around: ➤ Unlocking progress in neurology: How to build the case for a new target ➤ Immunity and inflammation inflection point: What determines the direction from here? Thank you to our Grand Rounds IV: The Disease Biology Boom panelists, moderators and emcee: Jamil M. Beg, SV Health Investors Gwendolyn Binder PhD, Cabaletta Bio Ellen Cahir-McFarland, Abata Therapeutics Nancy Cox, Vanderbilt University Medical Center Aaron Esser-Kahn, University of Chicago Aniket Kaloti, Leerink Partners Selina Koch, PhD, BioCentury Inc. Daniel Reich, NIH Clinical Center (CC) Jill C Richardson FRSB, MSD (Merck) Adam Savitz, Alto Neuroscience Paul Peter Tak, MD PhD FMedSci, Candel Therapeutics
-
Valuable insights from Robert Carnahan, Professor of Pediatrics and Associate Director of the Vanderbilt Vaccine Center at Vanderbilt University Medical Center, on the key lessons COVID-19 has provided for advancing vaccine development. A special thanks to Luciana Borio, Venture Partner at ARCH Venture Partners, for moderating this engaging lunch plenary.
-
The collaboration between academics, who drive data and methodological innovation, and industry, which applies these tools to uncover disease mechanisms, could greatly enhance discovery R&D, though the path remains complex. At #BioCenturyGrandRounds, the Human Data Revolution Session identified what must take place to make these data troves fit for purpose: ➤ Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity ➤ Data-for-purpose: Go big, go deep, or go long? Thank you to our Grand Rounds III: The Human Data Revolution panelists and moderators: Amy Abernethy, Former FDA Gonçalo Abecasis, Regeneron Daniel Burkhardt, Cellarity Caroline Chung, MD Anderson Cancer Center David B. Goldstein, Actio Biosciences, Inc. Colin Hill, Aitia Mathai Mammen, M.D., Ph.D., FogPharma Marissa Saunders, Recursion Elizabeth Ann Stringer, NashBio Karen Tkach Tuzman, BioCentury Inc. Wei-Qi Wei, Vanderbilt University Medical Center
-
Diving into meaningful conversations with industry and academic KOLs this morning at #BioCenturyGrandRounds: ➤ Keynote address from Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University on blowing up the small molecule paradigm: "No divine entity said these targets are undruggable, people said they were undruggable." ➤ Fireside Chat with Anil Shanker, Ph.D., Senior Vice President for Research and Innovation and Professor of Biochemistry, Cancer Biology, Neuroscience, and Pharmacology at Meharry Medical College on increasing diversity and building trust with underrepresented populations in clinical research.
-
Today is another full day of strategic sessions and networking opportunities you won't want to miss at #BioCenturyGrandRounds! Thank you to our Breakfast Workshop panelists and moderators for kicking off each day with insightful sessions on corporate formation and commercialization: jory bell, Playground Global Chris Garabedian, Xontogeny Reagan Jarvis, Anocca Guru Laxmikanthan, Nutter Charmaine Lykins, MapLight Therapeutics, Inc. Art Pappas, Pappas Capital Eric Pierce, BioCentury Inc. Jim Ray, MD Anderson Cancer Center Joel Sandler, Ph.D., Ipsos Healthcare Advisory Evonne Sepsis, ESC Advisors Asish Xavier, Johnson & Johnson
-
+1
-
Amy Abernethy and Brad Hirsch create Highlander Health to advance learning healthcare system.
Highlander to invest in creating a learning healthcare system
biocentury.com
-
As the first full day of #BioCenturyGrandRounds concluded, a panel of biopharma execs, VCs, and academic leaders explored how to join forces to find the next generation of breakthrough treatments early and bring them to market within years, not decades. The evening also featured a Poster Spotlight Networking Reception, with 45+ posters highlighting innovations in translation, followed by 'Rounds About Town,' where the networking continues at Nashville's iconic music venues. Join us tomorrow for another full day of session. On-site registration is available starting at 8AM at the Four Seasons Nashville. Didn't make it to Nashville? Register for a digital pass to access recording of all sessions: https://lnkd.in/gmhZ75vm Thank you to today's closing panelists and moderators: Daniel von Bornstädt, McKinsey & Company Stacy Feld, Johnson & Johnson Stephen Fesik, Vanderbilt University Sophie P. Kornowski, Boston Pharmaceuticals Jerome Van Biervliet, VIB
-
Academic innovators have driven groundbreaking technologies like CRISPR, gene therapies, CAR T, and mRNA. The handoff to industry is allowing such discoveries to reach patients, but some of these transformations must overcome limitations that cap their use. At #BioCenturyGrandRounds, the Modality Groundbreaker Session spotlighted potential solutions and guide drug developers on prioritizing innovations for efficient patient treatment: ➤ The heyday of AAV engineering is here: Will it deliver? ➤ The regenerative moment: Are iPSCs poised to reshape the cell therapy toolbox? ➤ Maximizing the impact of gene editing: Incremental improvements, or leaps to newer technologies? ➤ Souping up cancer cell therapies: Is the juice worth the squeeze? Registration is available on-site at Four Seasons Nashville, or register for a digital pass to watch recordings of the sessions at https://lnkd.in/gmhZ75vm. Thank you to our Grand Rounds II: Modality Groundbreakers panelists and moderators: Andrew Bellinger, Verve Therapeutics Zandy Forbes, MeiraGTx Erin Kimbrel, Astellas Pharma Samuel Lynch, Vanderbilt University Medical Center Marinna Madrid, PhD, Cellino Biotech Clare Murray, Life Edit Therapeutics Greg Newby, The Johns Hopkins University Stephanie Oestreich, myeloma investment fund Deborah Palestrant, 5AM Ventures Becky Pferdehirt, PhD, Andreessen Horowitz Lexi Rovner, 64x Bio Krishnendu Roy, Vanderbilt University Florencia Pereyra Segal, MPM BioImpact Henning Stennicke, Spur Therapeutics